Leidos secures $105.5 million contract for Naval health research
Investing.com -- Leidos Inc. has been awarded a $105.5 million contract by the U.S. Department of Defense to provide operational readiness research support services for the Naval Health Research Center.
The single-award, cost-plus-fixed-fee, indefinite-delivery/indefinite-quantity contract will involve investigative studies including planning, coordinating, designing, and executing experimental protocols.
The contract includes a 60-month ordering period with no options. Work will begin in September 2025 and is expected to be completed by September 2030.
The majority of the work (80%) will be performed in San Diego, California, with the remaining 20% taking place at Leidos’ location in Reston, Virginia.
The DoD will initially obligate $1,000 in fiscal 2025 research, development, test and evaluation funds from the Navy. These funds will not expire at the end of the current fiscal year.
Subsequent task orders under the contract will be funded with appropriate fiscal research, development, test and evaluation funds from the Navy.
The contract was awarded through a competitive procurement process via the system for award management (SAM.gov) as an unrestricted competition. Two offers were received before the Naval Supply Systems Command Fleet Logistics Center Norfolk’s Contracting Department in Philadelphia made the final selection.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
With LDOS making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed LDOS alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including LDOS, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is LDOS poised for similar growth? Don't miss the opportunity to find out.
